You have had Lyme disease for three years. You have watched vaccine conversations circle, seen two clinical programs slow down or stall, and quietly stopped expecting good news from research headlines. On March 23, 2026, Pfizer and Valneva announced that their Lyme vaccine candidate passed its Phase 3 VALOR trial with 74 percent efficacy — the best efficacy data ever published for a Lyme vaccine, covering adults and children aged 5 and older.
Now you're wondering what it means for you.
The honest explanation
The vaccine is called PF-07307405 (previously known as VLA15 or LB6V). It is a protein subunit vaccine targeting OspA — outer surface protein A — on the surface of Borrelia burgdorferi, the bacterium that causes Lyme disease. The "six-valent" part means it covers six different OspA serotypes, which map to the main Borrelia species circulating in North America and Europe.
The Phase 3 VALOR trial enrolled participants across endemic areas in the United States, Canada, and Europe. Over a full tick season, the vaccine prevented 73 to 75 percent of confirmed Lyme disease cases. An independent Data Safety Monitoring Board found no safety concerns. Pfizer plans to file for FDA approval and European regulatory clearance in 2026.
That last sentence matters. If those filings go smoothly, this becomes the first Lyme vaccine available in the United States since LYMErix was pulled from the market in 2002. That withdrawal had nothing to do with confirmed harm — it happened after a lawsuit (later contradicted by peer-reviewed research) suggested the vaccine might trigger arthritis in genetically susceptible people. Public fear killed the market before regulators acted. VLA15 uses a different OspA design specifically chosen to sidestep that concern.
The question chronic patients ask first
Does this vaccine help me?
Not directly. The vaccine is prophylactic. It prevents initial infection by priming your immune system to neutralize Borrelia while the bacterium is still in the tick, before it crosses into human skin. It does nothing to clear an existing infection, reduce your current symptom burden, or shorten treatment.
If you already have Lyme disease, this vaccine will not change your clinical picture.
What it might do, depending on your situation:
- Protect family members in the same household who live in endemic areas and have not yet been infected.
- Protect you from reinfection if your current illness resolves and you continue spending time in tick habitat.
- Become relevant in post-approval studies of booster dosing in previously treated patients — but that is speculative, and no such trial exists yet.
Most LLMD patients land in the same place: this is not for me right now, but it matters for people around me.
What 74 percent efficacy actually means
Efficacy numbers get misread. In the VALOR trial, vaccinated participants had 74 percent fewer confirmed Lyme cases than the placebo group over one tick season. That does not mean the vaccine fails one person in four. Your actual protection depends heavily on tick exposure and local infection rates in your area.
For context: seasonal flu vaccine efficacy sits between 40 and 60 percent in most years. The measles vaccine runs above 97 percent. Lyme at 74 percent lands in a reasonable middle — not sterilizing immunity, but a meaningful reduction for anyone spending regular time in high-risk environments.
The primary series requires four doses. Pfizer and Valneva expect a yearly pre-season booster will be needed to maintain protection, similar to flu shots.
What patients report
Most chronic Lyme patients who have watched this news have a consistent reaction: relief for people who haven't been diagnosed yet, combined with a quiet wariness born from watching LYMErix disappear and previous vaccine candidates stall. The concern is not about the science — it is about whether approval will hit the same political and legal friction it did in 2002.
There is also real curiosity from patients in remission about whether vaccination makes sense for them going forward. The honest answer is that the VALOR trial did not enroll a previously-infected cohort as a separate arm, so the data is thin. That may change in post-approval follow-up studies, but the FDA filing doesn't require that data for initial approval.
The patients who feel most directly affected are parents. Lyme incidence in children aged 5 to 15 is among the highest of any age group. A vaccine that covers ages 5 and older is something pediatricians in endemic states have not been able to offer before.
What tracking looks like in practice
Even if the vaccine is not right for you now, this is a good moment to build a documented symptom baseline. Here is why: when a new element enters your picture — a family member getting vaccinated, a protocol change, a new treatment starting — having a clean record from the weeks before makes it much easier to tell later whether anything actually shifted.
A simple example:
Three weeks before a family member gets vaccinated: Fatigue 2/5. Joint pain 1/5. Brain fog 2/5. Sleep averaging 6.5 hours. Stress moderate (logged as factor). Two weeks after: Joint pain 2/5. No other change. (Stress from a work deadline, logged the same day.) Four weeks after: Joint pain back to 1/5. No sustained shift.
That record tells you — and your LLMD — that the joint flare at week two matched a logged stressor, not a new pattern. Without those entries, week two looks ambiguous. With them, it is not.
The same logic applies whenever you are considering vaccination yourself once the clinical data for previously-treated patients matures. A solid three-to-four-week baseline before any clinical event gives you something concrete to compare against afterward.
How LymeTrack handles it
LymeTrack's 5-step daily check-in (CheckIn1Screen through CheckIn5Screen) is built for exactly this kind of before-and-after baseline work. Each day you score your active symptoms on a 1-to-5 scale with descriptive levels at each step, log your factors (sleep, stress, activity, weather, diet), and those entries accumulate in the Insights view over time.
To mark vaccination as an event, you can create a custom treatment definition in LymeTrack's treatment settings, note the dose and date, and then watch the Compass view (InsightsScreen) to see whether your symptoms shift in any direction afterward. The treatment-symptom correlation pulls from that same data, so any connection — or absence of one — shows up clearly in the timeline.
When you see your LLMD, the doctor-shareable report can export weeks of data around any clinical event. That gives your provider the full picture rather than a verbal summary that is always incomplete by the time you sit down in the exam room.
Further reading
- Pfizer and Valneva: Phase 3 VALOR Trial Announcement. The original March 2026 press release with full efficacy and safety data from the trial.
- Global Lyme Alliance: Is There a Vaccine for Lyme Disease?. Patient-facing overview of vaccine history, how OspA-targeting vaccines work, and the current development pipeline.
- CDC: Lyme Disease Vaccine. The CDC's current page on the state of Lyme vaccines, including what to expect as the regulatory process unfolds.
LymeTrack is a tracking tool, not medical advice. Talk to your LLMD or treating physician before changing a treatment plan.